Which treatments for drug-resistant TB are cost effective?
Measuring the cost, cost-effectiveness and efficiency gains of introducing modified short treatment for multidrug or rifampicin-resistance tuberculosis in Belarus, Georgia, Kazakhstan and Moldova
Country Focus
Belarus | Georgia | Kazakhstan | Moldova
Why was this work needed?
The Eastern Europe and Central Asia region has historically focused on hospital-based tuberculosis care, contributing to high rates of drug-resistant tuberculosis. The World Health Organisation (WHO) is now recommending innovative treatment regimens, in particular, modified shorter-course oral treatment regimens, to address these challenges. This project aimed to assess the cost-effectiveness of modified shorter-course oral treatment regimens compared with standard treatment for drug-resistant tuberculosis in four representative countries.
What did we do?
-
Assessed the cost-effectiveness of modified shorter-course oral treatment regimens compared to standard tuberculosis care.
-
Analysed treatment outcomes and provider costs in the context of drug-resistant tuberculosis management.